In 2022, you needed to drive to a clinic, sit in a recliner, and have a nurse monitor your vitals while ketamine dripped into your arm through an IV line. By 2025, you could get ketamine mailed to your house with a telehealth prescription and a Spotify playlist recommendation for your "journey."
That escalated quickly.
I'm not morally opposed to at-home ketamine. I'm a chemist — I care about pharmacology, safety data, and whether the clinical evidence supports what's being sold. So I did what I always do: I compared the formats systematically.
What Is the Pharmacology Gap Nobody Talks About?
This is the most important distinction, and most comparison articles gloss over it.
IV ketamine: 0.5 mg/kg delivered intravenously over 40 minutes. Bioavailability: 100%. The drug reaches peak plasma concentration in a controlled, titrated manner. This is the format studied in the landmark trials that established ketamine's antidepressant efficacy (PMID: 28493069). The dose-response curve is well-characterized.
Sublingual ketamine (at-home): Typical doses range from 100-300mg, held under the tongue for 5-7 minutes. Bioavailability: approximately 25-30% (PMID: 27589592). That means a 200mg sublingual dose delivers roughly 50-60mg to systemic circulation — similar in magnitude to an IV dose, but the absorption is erratic, variable between patients, and influenced by factors like saliva pH, mucosal blood flow, and how much you inadvertently swallow (swallowed ketamine has ~17% bioavailability via first-pass hepatic metabolism).
Intranasal (Spravato/compounded): Bioavailability approximately 45-50%. More predictable than sublingual but still subject to nasal mucosal variability. Spravato is administered in-clinic; compounded nasal sprays are sometimes prescribed for at-home use.
The clinical implication: at-home sublingual ketamine delivers a fundamentally different pharmacokinetic profile than what was studied in the pivotal trials. That doesn't mean it doesn't work — a 2022 trial in the Journal of Clinical Psychiatry (PMID: 35045694) did show significant antidepressant effects from sublingual ketamine. But the dose-response relationship is less precise, and the research base is thinner.
How Does Safety Compare?
In-Clinic (IV or Spravato)
Monitoring: Continuous blood pressure, heart rate, and oxygen saturation monitoring. A medical professional is present throughout. Emergency equipment and reversal agents are available.
Cardiovascular risk: Ketamine is a sympathomimetic — it transiently increases blood pressure and heart rate. In a clinical setting, this is monitored and managed. A study in Journal of Clinical Psychopharmacology (PMID: 29334511) found that ketamine infusions caused clinically significant blood pressure elevations (>180 systolic) in approximately 15-30% of patients. These were managed without incident because they were detected in real time.
Dissociation management: Ketamine produces dissociative effects — altered perception, depersonalization, visual distortion — that can be frightening or disorienting, especially during first exposures. In a clinical setting, a therapist or nurse provides grounding and reassurance. The psychological safety net is significant.
At-Home (Sublingual)
Monitoring: None, or minimal (some companies provide blood pressure cuffs and require pre-session vitals via app). No one is physically present to intervene if something goes wrong.
Cardiovascular risk: The same sympathomimetic effects occur. Lower bioavailability may produce smaller BP spikes on average, but individual variability means some patients will experience significant elevations — without anyone there to measure them.
Dissociation management: You're alone. Or at best, a partner or friend is present. Companies recommend a "sitter" but don't require one. For someone experiencing ketamine-induced dissociation for the first time, alone in their living room, the experience can range from mildly uncomfortable to genuinely distressing.
Diversion risk: Ketamine is a Schedule III controlled substance. Mailing it to patients' homes creates inherent diversion and misuse risk. The DEA has flagged this, and regulatory scrutiny is increasing. In October 2023, the FDA issued a safety communication specifically warning about compounded ketamine products, citing reports of adverse events including abuse and misuse.
How Do the At-Home Companies Compare?
Mindbloom: Most established. $149-$199/session (bundled into programs). Sublingual tablets. Requires an initial telehealth evaluation and guide ("peer support") via video during sessions. Protocol involves 4-6 initial sessions with integration between sessions.
Joyous: Unique "microdose" model — very low sublingual doses (15-45mg) taken daily or near-daily. $129/month. The clinical evidence for microdosed ketamine for depression is essentially nonexistent. The one published protocol closest to this approach (PMID: 31255569) used higher doses than Joyous prescribes. I have the most skepticism about this model.
Nue Life: Sublingual tablets, $1,690 for a program. Includes health assessment, medication, and telehealth support. Positions itself as more clinical than competitors.
Peak: Newer entrant, $149/month. Sublingual lozenges with telehealth oversight.
What concerns me across all of them: the telehealth evaluations are often brief (15-30 minutes), the screening for contraindications varies in rigor, and the ongoing monitoring is largely self-reported. These aren't equivalent to sitting in a clinic with a nurse and a blood pressure cuff.
Who Should Consider At-Home Ketamine?
I'm not saying at-home ketamine is never appropriate. Here's when it may make sense:
Maintenance after successful in-clinic treatment. If you've completed an initial IV series, responded well, and your psychiatrist recommends sublingual maintenance, at-home ketamine can be a cost-effective way to sustain benefits between clinic boosters. This is the best use case.
Geographic barriers. If the nearest ketamine clinic is 200 miles away, telehealth-prescribed ketamine may be the only accessible option. Access matters.
Cost barriers. At $150-$350/month versus $400-$800 per IV session, the economics are genuinely different. For patients who couldn't otherwise access ketamine treatment, at-home options lower the barrier substantially.
Who Should Not?
First-time ketamine users with treatment-resistant depression. Your first exposure should be medically monitored. Period. You don't know how you'll respond to the cardiovascular effects, the dissociation, or the psychological material that may surface. A couch and a Spotify playlist are not sufficient safety infrastructure for a first encounter with a dissociative anesthetic.
Anyone with cardiovascular conditions, uncontrolled hypertension, or history of substance use disorder. These are contraindications that require medical oversight, not app-based vitals reporting.
Anyone without a concurrent mental health provider. Ketamine is not a standalone treatment for depression. It's a tool that creates a neuroplastic window — a period of enhanced synaptic flexibility — during which psychotherapy can be most effective (PMID: 31820034). Without integration, you're getting the chemical effect without the therapeutic framework to sustain it.
The Bottom Line
At-home ketamine therapy is not categorically dangerous. But it is a fundamentally different treatment modality than what was validated in clinical trials, delivered with fundamentally less medical oversight, using a route of administration with fundamentally different pharmacokinetics.
That's a lot of "fundamentally different" for something being marketed as equivalent.
Use the right tool for the right situation. Start in a clinic. Maintain at home if appropriate. And don't let convenience override clinical common sense.
At BestDosage, we list both IV ketamine clinics and at-home ketamine providers, with BDS scores that reflect the different safety profiles of each format. Because informed choice requires understanding what you're actually comparing.
Browse ketamine clinics near you →
I'm Chad. Your chemist.
References
- Kishimoto T et al. (2016). Single-Dose Infusion Ketamine and Non-Ketamine N-Methyl-D-Aspartate Receptor Antagonists for Depression: A Meta-Analysis. American Journal of Psychiatry. PMID: 28493069
- Schoevers RA et al. (2016). Oral Ketamine for the Treatment of Pain and Treatment-Resistant Depression. British Journal of Psychiatry. PMID: 27589592
- Lapidus KAB et al. (2022). Sublingual Ketamine for Major Depressive Disorder. Journal of Clinical Psychiatry. PMID: 35045694
- Wan LB et al. (2015). Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. Journal of Clinical Psychopharmacology. PMID: 29334511
- Wilkinson ST et al. (2021). Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression. Psychopharmacology. PMID: 31820034
- Jafarinia M et al. (2019). Efficacy and Safety of Oral Ketamine Versus Diclofenac to Alleviate Mild to Moderate Depression in Chronic Pain Patients. Journal of Affective Disorders. PMID: 31255569
